STOCK TITAN

IRONWOOD PHARMACEUTICALS (IRWD) SEC Filings

IRWD NASDAQ

Ironwood Pharmaceuticals, Inc. filings document a Nasdaq-listed biotechnology company focused on gastrointestinal and rare disease therapies. Its Form 8-K reports include operating and financial results, business updates for LINZESS and apraglutide, regulatory and pricing matters involving LINZESS, and financing-related disclosures tied to credit agreements and liquidity conditions.

Proxy filings cover board elections, executive compensation votes, equity incentive plan matters, auditor ratification, and annual meeting procedures. Other filings address governance changes, Nasdaq listing-compliance matters for its Class A common stock, and the registered security structure of IRWD shares on the Nasdaq Global Select Market.

Rhea-AI Summary

Ironwood Pharmaceuticals (IRWD) Chief Commercial Officer Tammi L. Gaskins reported a sale of 5,919 shares of Class A common stock at $4.81 per share on November 16, 2026. The shares were automatically sold to cover tax withholding tied to restricted stock unit vesting; the transaction was not discretionary. Gaskins directly held 344,431 shares afterward. No Rule 10b5-1 plan is reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.46%
Tags
insider
-
Rhea-AI Summary

Ironwood Pharmaceuticals, Inc. (IRWD) is the issuer of the Class A common stock covered in an amended ownership report by Armistice Capital, LLC and Steven Boyd. As of September 30, 2026, they report beneficial ownership of 15,000,000 shares, or 9.08% of the class, with shared voting and dispositive power over all 15,000,000 shares and no sole voting or dispositive power. Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder; Steven Boyd is Armistice Capital’s managing member and may be deemed to beneficially own the shares. The Master Fund disclaims beneficial ownership because the Investment Management Agreement gives Armistice Capital voting and investment power.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
ownership
-
Rhea-AI Summary

Ironwood Pharmaceuticals Inc. (IRWD) officer Tammi L. Gaskins reported a planned sale of 6,666 Class A common shares, with an aggregate market value of $32,330.10 and an approximate sale date of November 16, 2026. The notice says the shares are to cover taxes from vesting stock awards. The shares were acquired through an 18,000-share restricted stock unit award granted December 11, 2024, under the company’s Amended and Restated 2019 EIP, subject to vesting requirements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
other
Rhea-AI Summary

Ironwood Pharmaceuticals Inc. (IRWD) is the issuer whose common stock State Street Corporation reported beneficial ownership of 6,723,774 shares, or 4.1%, as of September 30, 2026. State Street reported shared voting power over 6,516,093 shares and shared dispositive power over 6,723,774 shares, with no sole voting or dispositive power.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
ownership
-
Rhea-AI Summary

Ironwood Pharmaceuticals reported third-quarter 2026 collaborative arrangements revenue of $133.0 million, versus $122.1 million a year earlier, and net income of $59.8 million, versus $40.1 million. For the nine months ended September 30, 2026, revenue was $352.6 million, compared with $248.4 million in 2025, and net income was $151.9 million, compared with $26.3 million.

Net cash provided by operating activities for the nine months ended September 30, 2026 was $130.8 million, versus $52.5 million in 2025. Cash and cash equivalents were $86.4 million as of September 30, 2026, compared with $215.5 million as of December 31, 2025. Ironwood repaid the $200.0 million aggregate principal amount of its 2026 Convertible Notes upon maturity in June 2026 and made $60.0 million of repayments on its revolving credit facility during the nine months; the facility’s outstanding principal was $325.0 million as of September 30, 2026.

Ironwood initiated the 24-week global STARS-2 confirmatory Phase III trial of apraglutide in June 2026 and is actively recruiting patients. Subject to the trial results, the company plans to file for regulatory approval in 2029.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.93%
Tags
quarterly report
-
Rhea-AI Summary

Ironwood Pharmaceuticals (IRWD) reported third-quarter 2026 revenue of $133.040 million, compared with $122.060 million a year earlier. GAAP net income was $59.838 million, versus $40.080 million, and adjusted EBITDA was $97.925 million, versus $81.811 million. U.S. LINZESS net sales were $324.919 million in the quarter and $879.753 million for the first nine months.

Ironwood raised 2026 guidance to $1.20 billion–$1.25 billion for LINZESS U.S. net sales, $485 million–$510 million for total revenue and greater than $350 million for adjusted EBITDA. The revised ranges compare with prior guidance of $1.15 billion–$1.20 billion, $460 million–$485 million and greater than $310 million, respectively. The company said LINZESS guidance reflects improved net price and mid-single-digit percentage demand growth. The STARS-2 confirmatory Phase 3 trial of apraglutide is ongoing, with planned U.S. and global site expansion on track.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.90%
Tags
current report
Rhea-AI Summary

Ironwood Pharmaceuticals Inc. (IRWD) is the issuer of the Class A common stock for which Bank of America Corporation reports beneficial ownership of 5,219,315 shares, or 3.2%. The reported position carries shared voting and dispositive power over 5,219,315 shares, with zero sole voting or dispositive power. The percentage calculation uses 165,239,947 shares outstanding as of July 31, 2026, according to the issuer's Form 10-Q.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.85%
Tags
ownership
-
Rhea-AI Summary

Ironwood Pharmaceuticals (IRWD) appointed Tammi Gaskins, its Senior Vice President and Chief Commercial Officer, as CEO and a director, effective January 1, 2027. The board increased from eight to nine directors effective that date. Thomas McCourt will retire as CEO on December 31, 2026, and remain a director. Ironwood and McCourt plan to enter a consulting agreement effective January 1, with an anticipated fee of $10,000 per month.

As CEO, Gaskins will receive an annual base salary of $775,000 and an individual bonus target of 75% of her annual base salary, subject to achievement of corporate goals. Her target grant values are approximately $2,000,000 for RSUs and approximately $2,000,000 for PSUs at target performance. RSUs will vest over four years, with 25% vesting on each approximate anniversary; PSU vesting terms and performance period are expected to be determined in 2027. Ironwood intends an amended severance agreement effective January 1, 2027; after a qualifying termination, it would provide 18 months of base salary, or 24 months for a Change of Control Termination, plus specified bonus payments, up to 18 months of subsidized COBRA coverage and outplacement assistance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.16%
Tags
current report
-
Rhea-AI Summary

Ironwood Pharmaceuticals Inc. (IRWD) lists a proposed sale by former officer Michael Shetzline of 83,306 Class A common shares through E Trade Securities LLC, with an approximate sale date of September 24, 2026, on Nasdaq. The stated aggregate market value is $377,376.18. Shetzline stated that the shares are to be sold to cover taxes from vesting of stock awards.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.87%
Tags
other
Rhea-AI Summary

IRONWOOD PHARMACEUTICALS INC (symbol: IRWD) is the issuer of record for a Form 4 filing submitted to the SEC. DENNER ALEXANDER J reported acquisition or exercise transactions in this Form 4 filing.

IRONWOOD PHARMACEUTICALS INC (IRWD) reported that director Alexander J. Denner received an equity grant of 3,694 shares of Class A Common Stock on September 15, 2026. The shares were issued at no cash cost under the company’s Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, increasing his direct holdings to 327,549 shares. No Rule 10b5-1 trading plan is reported for this award.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.07%
Tags
insider

FAQ

How many IRONWOOD PHARMACEUTICALS (IRWD) SEC filings are available on StockTitan?

StockTitan tracks 85 SEC filings for IRONWOOD PHARMACEUTICALS (IRWD), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for IRONWOOD PHARMACEUTICALS (IRWD)?

The most recent SEC filing for IRONWOOD PHARMACEUTICALS (IRWD) was filed on November 18, 2026.